Cohance Extends Losses After USFDA Form 483 Observations

Cohance Lifesciences fell for a second session after its Telangana facility received four USFDA observations following a recent inspection. Cohance Lifesciences Ltd. (NSE:

) extended its decline for the second consecutive trading session on September 7, 2026, with the stock falling 1.54% to close at ₹449.55. The stock remains under pressure as investors assess the latest regulatory development. The United States Food and Drug Administration (USFDA) inspected the company's formulation (FDF) facility in Shamshabad, Telangana, between August 27 and September 4, 2026. The inspection concluded with the issuance of a Form FDA 483 containing four observations. Stock Snapshot Closing Price: ₹449.55 Change: -1.54% (-₹7.05) Market Capitalisation: ₹17,733 crore 52-Week Range: ₹266.70 – ₹1,038.90 Despite the recent weakness, the stock has recovered more than 68% from its 52-week low of ₹266.70. However, it remains approximately 67% below its all-time high of ₹1,360, recorded in December 2024. The regulatory observations and the company's subsequent corrective actions are likely to remain key areas of focus for investors. Market participants will closely monitor management commentary and future regulatory updates to assess the potential impact on operations and business performance. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.